IL118202A0 - Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours - Google Patents

Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours

Info

Publication number
IL118202A0
IL118202A0 IL11820296A IL11820296A IL118202A0 IL 118202 A0 IL118202 A0 IL 118202A0 IL 11820296 A IL11820296 A IL 11820296A IL 11820296 A IL11820296 A IL 11820296A IL 118202 A0 IL118202 A0 IL 118202A0
Authority
IL
Israel
Prior art keywords
hours
active ingredient
parathyroid hormone
administration form
release period
Prior art date
Application number
IL11820296A
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of IL118202A0 publication Critical patent/IL118202A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL11820296A 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours IL118202A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19517430A DE19517430A1 (en) 1995-05-12 1995-05-12 Pharmaceutical dosage form of parathyroid hormone with a two to six hour drug release period

Publications (1)

Publication Number Publication Date
IL118202A0 true IL118202A0 (en) 1996-09-12

Family

ID=7761731

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11820296A IL118202A0 (en) 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours

Country Status (7)

Country Link
EP (1) EP0825872A1 (en)
JP (1) JPH11505222A (en)
AU (1) AU5816596A (en)
DE (1) DE19517430A1 (en)
IL (1) IL118202A0 (en)
WO (1) WO1996035447A1 (en)
ZA (1) ZA963714B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922467A3 (en) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretic drug delivery
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
WO2007059470A2 (en) 2005-11-10 2007-05-24 Board Of Control Of Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
JP2013512688A (en) 2009-12-07 2013-04-18 ミシガン テクノロジカル ユニバーシティ Methods of using black bear parathyroid hormone and black bear parathyroid hormone
LT2568806T (en) 2010-05-12 2016-09-26 Radius Health, Inc. Therapeutic regimens
JP5965909B2 (en) 2010-09-28 2016-08-10 ラジウス ヘルス，インコーポレイテッド Selective androgen receptor modulator
IL310069A (en) 2015-04-29 2024-03-01 Radius Pharmaceuticals Inc Methods of treating cancer
KR102397890B1 (en) 2016-06-22 2022-05-12 일립시스 파마 리미티드 AR+ Breast Cancer Treatment Method
WO2018129419A1 (en) 2017-01-05 2018-07-12 Radius Pharmaceuticals, Inc. Polymorphic forms of rad1901-2hcl
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
DE3935738A1 (en) * 1989-10-27 1991-05-08 Forssmann Wolf Georg DRUGS CONTAINING THE HUMAN PARATHORMONE FRAGMENT (1-37) AS AN ACTIVE AGENT
DE69429603T2 (en) * 1993-09-22 2002-08-14 Hisamitsu Pharmaceutical Co Iontophoresematrix

Also Published As

Publication number Publication date
AU5816596A (en) 1996-11-29
JPH11505222A (en) 1999-05-18
DE19517430A1 (en) 1996-11-14
ZA963714B (en) 1997-11-10
WO1996035447A1 (en) 1996-11-14
EP0825872A1 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
IL104192A0 (en) Pharmaceutical dosage forms having prolonged release rate of active ingredient
HUT60466A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
HUT59314A (en) Process for producing pharmaceutical composition comprising minocylcine active ingredient and suitable for a single daily administration
HUT64065A (en) Process for producing quinolone- and naphthyridonecarboxylic acid derivatives and pharmaceutical compositions comprising same as active ingredient
GB2143734B (en) Process for the preparation of sustained release pharmaceutical compositions having a high active ingredient content
EP0727217A3 (en) Pharmaceutical composition containing god-type ellagitannin as active ingredient
IL106326A (en) Analogs of parathyroid hormone, their production and pharmaceutical compositions containing them
HUP9901457A3 (en) Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
EP0224146A3 (en) Pharmaceutical preparation for the controlled release of active ingredients
GB8403138D0 (en) Sustained release of active ingredient
DK583789A (en) SYSTEM FOR TRANSMUCOSAL ADMINISTRATION OF THE ACTIVE INGREDIENT OF A MEDICINE
HUP0004383A2 (en) Pharmaceutical preparation comprising clodronate as active ingredient and silicified microcrystalline cellulose as excipient
IL70071A (en) Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
HUT49625A (en) Process for producing macrolid compounds and pharmaceutical compositions comprising such active ingredient
HUT58060A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
ZA968715B (en) Stable pharmaceutical forms of administration containing parathyroid hormone.
ZA988718B (en) Drug formulation having controlled release of active compound
IL118202A0 (en) Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours
PL332249A1 (en) Pharmaceutical microspheres of varproinic acid for oral administration
NZ244320A (en) Acylals of imidazole-5-carboxylic acid, preparation and pharmaceutical compositions thereof
HUT59319A (en) Pharmaceutical compositions with controlled release of active ingredient and process for producing same
ZA9610714B (en) Rapid release tablet comprising tolfenamic acid or a pharmaceutically acceptable salt thereof as active ingredient and a method of preparing such tablet
HUT47127A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising such active ingredient
HK1005131A1 (en) Improvement of physiological tolerance of pharmaceutical active beta-amio acids